Women’s health has spent decades as an afterthought in medicine — underfunded, under-researched, and underserved. FemTech is the correction. In 2026, the category has moved well past period-tracking apps into diagnostics, hormone therapy, fertility infrastructure, and menopause care that clinics, insurers, and employers actually pay for. Investors have noticed: global femtech funding is on track to top $1.8B across 2024–2026, and Europe — led by Germany, France, the UK, and the Nordics — has become one of the category’s most active testing grounds.
Here are the FemTech startups worth watching in 2026.
1. Clue (Berlin, Germany)
Founded in 2012, Clue is the startup that gave FemTech its name — literally: founder Ida Tin coined the term. The Berlin-based period and cycle-tracking app now serves more than 10 million users across 190 countries and remains the reference point every newer entrant gets compared to.
2. Natural Cycles (Stockholm, Sweden)
The first app to be FDA-cleared as a form of contraception, Natural Cycles turned basal body temperature and algorithmic cycle prediction into a genuine alternative to hormonal birth control. It remains one of the few consumer femtech products with a hard regulatory moat.
3. Flo Health (London, UK / Vilnius, Lithuania)
One of the most downloaded health apps in the world, Flo has evolved from a period tracker into a broader reproductive health platform valued north of $1B. Its scale gives it a data and distribution advantage few competitors can match.
4. Inne (Berlin, Germany)
Inne has raised roughly €16M to build a saliva-based hormone biosensor that gives women a real-time read on where they are in their fertile window — a more clinical alternative to app-only cycle tracking.
5. Daye (London, UK)
Daye started with CBD-infused tampons and has since expanded into at-home STI testing, hormone testing, and period pain treatment — building a full-stack gynecological health brand around a product most people still think of as commodity retail.
6. Womed (Paris, France)
Womed has developed a post-surgical device designed to prevent uterine scarring and adhesions after gynecological procedures — a clinical, reimbursement-track approach to a problem that has had no dedicated solution until now.
7. May Health (Paris, France)
May Health is building a minimally invasive treatment for polycystic ovary syndrome (PCOS), one of the most common — and most underfunded — hormonal conditions affecting women of reproductive age.
8. BrightHeart (Paris, France)
Fresh off an €11M Series A in early 2026, BrightHeart uses AI-driven ultrasound analysis to help clinicians detect congenital heart defects in fetuses earlier and more reliably than manual screening.
9. XbyX (Berlin, Germany)
XbyX is a digital platform helping women navigate menopause with personalized guidance, symptom tracking, and educational content — part of a wider wave of startups treating menopause as a category, not an afterthought.
10. Evela (Berlin, Germany)
Evela is pushing menopause care into the workplace, positioning it as an employee benefit companies offer alongside standard healthcare packages. It closed a €2.6M round in late 2025 to scale that pitch across European employers.
11. LEVY Health (Berlin, Germany)
LEVY Health builds clinical decision-support software for fertility diagnostics, helping doctors interpret complex hormonal and reproductive data faster — infrastructure playing in the background of the fertility boom rather than a consumer front end.
12. Samphire Neuroscience (London, UK)
Samphire is applying neurotech — non-invasive brain stimulation — to hormonal conditions like PMS and menopause symptoms, one of the more scientifically ambitious bets in the category and a repeat fundraiser through 2024–2026.
The bigger picture: the money is shifting from tracking apps toward things insurers and clinics can actually reimburse — diagnostics, devices, and care infrastructure for fertility, menopause, and hormonal health. Watch France in particular, which now has roughly 200 femtech startups and Europe’s first dedicated femtech investment fund, and Germany, which continues to produce the deepest bench of Series A-ready teams on the continent.
